Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20063792 | 0.69 | ANPEP (0.56) | ANPEPIDO1PLAUSLC18A3 | |
| SCHEMBL29687690 | 0.69 | ANPEP (0.56) | ANPEPIDO1PLAUSLC18A3 | |
| SCHEMBL29728630 | 0.69 | IDO1 (0.46) | ANPEPIDO1PLAUSLC18A3 | |
| SCHEMBL1990446 | 0.69 | ANPEP (0.56) | ANPEPIDO1PLAUSLC18A3 | |
| SCHEMBL73467 | 0.69 | IDO1 (0.46) | ANPEPIDO1PLAUSLC18A3 | |
| SCHEMBL20095994 | 0.69 | ANPEP (0.56) | ANPEPIDO1PLAUSLC18A3 | |
| SCHEMBL1990443 | 0.69 | ANPEP (0.56) | ANPEPIDO1PLAUSLC18A3 | |
| SCHEMBL6763553 | 0.68 | HTR2A (0.37) | ANPEP | |
| SCHEMBL6613669 | 0.68 | HTR2A (0.37) | ANPEP | |
| SCHEMBL6962983 | 0.68 | ANPEP (0.33) | ANPEPIDO1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432691-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | claimed |
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-04-01 | — | — | US | claimed |
| WO-2003040107-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | ANPEP 2366/4885IDO1 13/4885PLAU 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.